Monoclonal antibodies (mAbs) are essential biotherapeutics. Post-translational modification occurs during the entire drugs life cycle, increasing product complexity and heterogeneities that can affect quality and efficacy. The PhD project, in collaboration with the Istituto Superiore di Sanità, focused on charge and size variants that are considered Critical Quality Attributes that must be closely monitored. The aim was to design transversal analytical platforms for mAbs characterization and Quality Control (QC), principally following ICH guidelines and the Analytical Quality by Design approach. Charge variants were studied by imaged capillary isoelectric focusing technique, starting from the Ph. Eur. conditions and lead to two novel optimized methods with enhanced accuracy of pI measurement and applicability across different therapeutic mAbs. Furthermore, size variants were addressed with size exclusion chromatography technique to identify critical analytical parameters and optimize sensitivity and resolution. The results showed the importance of developing horizontal methods to support and standardize regulatory QC and post-marketing surveillance of mAb-based drugs.
Gli anticorpi monoclonali (mAbs) sono farmaci bioterapici essenziali. Durante il loro ciclo di vita subiscono modificazioni post-traduzionali che aumentano la complessità ed eterogeneità dei prodotti, influenzandone qualità ed efficacia. Il progetto di dottorato, in collaborazione con l’Istituto Superiore di Sanità, è stato incentrato su varianti di carica e di massa, che, essendo considerate attributi critici di qualità, devono essere monitorate con attenzione. L’obiettivo principale è stato lo sviluppo di piattaforme analitiche trasversali per la caratterizzazione e il controllo qualità (QC) dei mAbs, seguendo le linee guida ICH e l’approccio Analytical Quality by Design. Le varianti di carica sono state studiate tramite la tecnica di Imaged Capillary Isoelectric Focusing, partendo dalle condizioni di Ph. Eur. e portando a due nuovi metodi ottimizzati per valori di pI più accurati ed applicabili a diversi mAbs. Le varianti di massa sono state studiate con la tecnica di Size Exclusion Chromatography per identificarne i parametri critici e tendere ad ottimizzare sensibilità e risoluzione. I risultati evidenziano l’importanza di sviluppare metodi orizzontali a supporto delle attività di QC e della sorveglianza post-marketing.
Development Of Horizontal Analytical Platforms To Be Used For Monoclonal Antibodies Quality Control
GHIZZANI, VIRGINIA
2026
Abstract
Monoclonal antibodies (mAbs) are essential biotherapeutics. Post-translational modification occurs during the entire drugs life cycle, increasing product complexity and heterogeneities that can affect quality and efficacy. The PhD project, in collaboration with the Istituto Superiore di Sanità, focused on charge and size variants that are considered Critical Quality Attributes that must be closely monitored. The aim was to design transversal analytical platforms for mAbs characterization and Quality Control (QC), principally following ICH guidelines and the Analytical Quality by Design approach. Charge variants were studied by imaged capillary isoelectric focusing technique, starting from the Ph. Eur. conditions and lead to two novel optimized methods with enhanced accuracy of pI measurement and applicability across different therapeutic mAbs. Furthermore, size variants were addressed with size exclusion chromatography technique to identify critical analytical parameters and optimize sensitivity and resolution. The results showed the importance of developing horizontal methods to support and standardize regulatory QC and post-marketing surveillance of mAb-based drugs.| File | Dimensione | Formato | |
|---|---|---|---|
|
GHIZZANI_PhD thesis.pdf
embargo fino al 11/08/2027
Licenza:
Tutti i diritti riservati
Dimensione
15.89 MB
Formato
Adobe PDF
|
15.89 MB | Adobe PDF |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.14242/355935
URN:NBN:IT:UNIPV-355935